Strides Shasun on Wednesday said it has received approval from the US health regulator for memantine hydrochloride tablets used in the treatment of dementia.
The product will be manufactured at the company's facility at Bengaluru and marketed by Strides Pharma Inc in the US market.
In a BSE filing, Strides Shasun said it has received approval from the United States Food and Drug Administration (USFDA) for memantine hydrochloride tablets USP, 5mg and 10 mg.
"The product will be launched immediately," it added.
Quoting IMS sales data, Strides Shasun said the US market for memantine hydrochloride tablets USP, 5mg and 10 mg is approximately $60 million.
Strides Shasun stock was trading 6.25 per cent lower at Rs 849.85 on the BSE.
